Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Follow-Up Questions
Scinai Immunotherapeutics Ltd (SCNI)'in P/E oranı nedir?
Scinai Immunotherapeutics Ltd 'in P/E oranı 0.2837 'dir
Scinai Immunotherapeutics Ltd 'in CEO'su kimdir?
Mr. Amir Reichman 2021 'den beri şirketle birlikte olan Scinai Immunotherapeutics Ltd 'in Chief Executive Officer 'ıdır.
SCNI hissesinin fiyat performansı nasıl?
SCNI 'in mevcut fiyatı $1.57 'dir, son işlem günde 0.64% increased etti.
Scinai Immunotherapeutics Ltd için ana iş temaları veya sektörler nelerdir?
Scinai Immunotherapeutics Ltd Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 3 analist Scinai Immunotherapeutics Ltd için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 4 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir
